UK Competition Body Backs Up Claim That Pfizer & Flynn Abused Dominant Position With ‘Excessive’ Prices

 
• By Ian Schofield
  
Symbol of law and justice
The CMA has outlined why it thinks Pfizer and Flynn abused a dominant position

More from Pricing Debate

More from Market Access